Medifast (NYSE:MED - Get Free Report) issued an update on its fourth quarter 2024 earnings guidance on Monday morning. The company provided EPS guidance of 0.100-0.650 for the period, compared to the consensus EPS estimate of -0.180. The company issued revenue guidance of $100.0 million-$120.0 million, compared to the consensus revenue estimate of $130.0 million.
Analyst Upgrades and Downgrades
Separately, DA Davidson reissued an "underperform" rating and issued a $17.50 target price on shares of Medifast in a research report on Monday, July 22nd.
Check Out Our Latest Report on MED
Medifast Stock Up 1.2 %
Shares of Medifast stock traded up $0.23 on Monday, hitting $18.81. 206,085 shares of the company's stock traded hands, compared to its average volume of 390,565. Medifast has a 52-week low of $17.07 and a 52-week high of $76.42. The stock has a market cap of $205.72 million, a P/E ratio of 7.04 and a beta of 1.13. The firm's 50-day moving average is $18.44 and its 200 day moving average is $21.10.
Medifast (NYSE:MED - Get Free Report) last issued its earnings results on Monday, August 5th. The specialty retailer reported $0.92 earnings per share (EPS) for the quarter, topping analysts' consensus estimates of $0.36 by $0.56. The business had revenue of $168.56 million for the quarter, compared to analysts' expectations of $160.44 million. Medifast had a return on equity of 25.77% and a net margin of 3.81%. During the same period in the previous year, the firm posted $2.77 EPS. Equities research analysts forecast that Medifast will post 1.12 EPS for the current year.
Medifast Company Profile
(
Get Free Report)
Medifast, Inc, through its subsidiaries, engages in the manufacture and sale of weight loss, weight management, and healthy living products in the United States and the Asia-Pacific. It offers bars, puffs, cereal, crunchers, drinks, hearty choices, oatmeal, pancakes, pudding, soft serve, shakes, smoothies, soft bakes, and soups under the OPTAVIA, OPTAVIA ACTIVE, and Optimal Health brand names.
Further Reading
This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.
Before you consider Medifast, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Medifast wasn't on the list.
While Medifast currently has a "Hold" rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Options trading isn’t just for the Wall Street elite; it’s an accessible strategy for anyone armed with the proper knowledge. Think of options as a strategic toolkit, with each tool designed for a specific financial task. Keep reading to learn how options trading can help you use the market’s volatility to your advantage.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
